SEC Form 4 research
| Issuer | Opus Genetics, Inc. |
|---|---|
| Tickers | OCUP, IRD, RNN, RXHN, RXHN.OB |
| Reporting owners | 44 |
| Officers and directors | 30 |
| Last public filing | 2026-10-02 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-02 | 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund, Foundation Fighting Blindness, Inc. | S | 556,000 | $4.96 | Not reported |
| 2026-09-08 | 2026-09-03 | Gagnon Robert E. | S | 28,000 | $4.54 | Not reported |
| 2026-07-27 | 2026-07-23 | YERXA BENJAMIN R | S | 7,429 | $2.97 | Not reported |
| 2026-07-27 | 2026-07-23 | SCHACHLE JOSEPH K | S | 4,644 | $2.94 | Not reported |
| 2026-07-27 | 2026-07-23 | Magrath George | S | 9,475 | $2.95 | Not reported |
| 2026-07-27 | 2026-07-23 | Gagnon Robert E. | S | 7,783 | $2.95 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.